No Data
No Data
Cosciens Biopharma Brief: Says Additional Time May Be Required to Address "Certain Matters" Related to 2024 All Stock Merger Transaction With Ceapro
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial With Avenanthramides as a Potential Anti-Inflammatory Product
Cosciens Biopharma Down 3.3% As Repositions as Life Sciences Business
COSCIENS Biopharma Inc. Outlines Strategic Focus on Natural-Based Health and Wellness Products
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization